THOUSAND OAKS, Calif., Jan. 14 Amgen (Nasdaq: AMGN) today announced that the company will donate $2 million to Haiti relief efforts. Amgen staff are being encouraged to be generous and that effort should also generate meaningful additional support.
The Amgen Foundation will deploy its Disaster Relief Program web site for Amgen staff around the globe who wish to contribute their own funds to designated organizations aiding in the relief and rebuilding efforts. The Amgen Foundation will match staff contributions dollar for dollar via this relief site.
"The earthquake that hit Haiti this week has devastated the lives of hundreds of thousands of people in Port-au-Prince and beyond," said Kevin Sharer, Amgen's chairman and chief executive officer. "The contributions are expressions of our sincere sympathy for those directly affected by this tragedy."
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
About the Amgen Foundation
The Amgen Foundation (www.amgen.com/citizenship/overview.html) seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live and work. Since 1991, the Foundation has made more than $140 million in grants to nonprofit organizations throughout the United States, Puerto Rico and Europe that impact society in inspiring and innovative ways, and those that provide disaster relief efforts internationally.
CONTACT: Amgen Kristen Davis, (805) 447-3008